menu
    • menu

    Company profile for Nectero Medical

    NEW Drugs in Dev: 2
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Nectero Medical is developing a novel treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms (AAA). The Nectero EAST®, or Endovascular Aneurysm Stabilization Treatment System, delivers a compound with a proprietary molecule known as a Stabilizer Agent to the site of the aneurysm. Inhibits further breakdown of the aneurysm by disrupting the “aortic degradation process”. Strengthens the...
    Nectero Medical is developing a novel treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms (AAA). The Nectero EAST®, or Endovascular Aneurysm Stabilization Treatment System, delivers a compound with a proprietary molecule known as a Stabilizer Agent to the site of the aneurysm. Inhibits further breakdown of the aneurysm by disrupting the “aortic degradation process”. Strengthens the vessel wall by cross-linking within the tissue; this wall strengthening lowers the risk of rupture Our technology allows for earlier intervention in a much safer manner

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Nectero MedicalUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    515 S 48th St, Suite 101, Tempe, Arizona 85281
    Telephone
    Telephone
    (866) 755-4744
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://necteromedical.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/nectero-medical-inc
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Natural Product Expo West

    Natural Product Expo West

    Not Confirmed

    envelop Contact Supplier

    Natural Product Expo West

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nectero Medical Secures CPT Codes for AAA Therapy
    Nectero Medical Secures CPT Codes for AAA Therapy

    12 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/12/3098256/0/en/Nectero-Medical-Secures-Category-III-CPT-Codes-for-Investigational-Therapy-to-Treat-Small-to-Medium-Sized-AAAs.html

    GLOBENEWSWIRE
    12 Jun 2025
    Share Share
    Nectero Medical Recognized as a 2024 AZBio Fast Lane Award Winner
    Nectero Medical Recognized as a 2024 AZBio Fast Lane Award Winner

    24 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/24/2952069/0/en/Nectero-Medical-Recognized-as-a-2024-AZBio-Fast-Lane-Award-Winner.html

    GLOBENEWSWIRE
    24 Sep 2024
    Share Share
    Nectero Medical Announces Completion of $96M Series D Financing
    Nectero Medical Announces Completion of $96M Series D Financing

    11 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240411504127/en

    BUSINESSWIRE
    11 Apr 2024
    Share Share
    Nectero Announces Initiation of Phase II/III Trial of the Nectero EAST System
    Nectero Announces Initiation of Phase II/III Trial of the Nectero EAST System

    18 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240118425249/en

    BUSINESSWIRE
    18 Jan 2024
    Share Share
    Nectero Granted Breakthrough Therapy Designation for the Nectero EAST® System
    Nectero Granted Breakthrough Therapy Designation for the Nectero EAST® System

    01 Nov 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231101852046/en

    BUSINESSWIRE
    01 Nov 2023
    Share Share
    Nectero Medical Receives FDA Fast Track Designation for Nectero EAST® System
    Nectero Medical Receives FDA Fast Track Designation for Nectero EAST® System

    24 Aug 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230824907837/en

    BUSINESSWIRE
    24 Aug 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search